TY - JOUR T1 - Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00337-2022 VL - 8 IS - 4 SP - 00337-2022 AU - Yuriko Ishida AU - Satoshi Ikeda AU - Akimasa Sekine AU - Tomohisa Baba AU - Takashi Ogura Y1 - 2022/10/01 UR - http://openres.ersjournals.com/content/8/4/00337-2022.abstract N2 - We have read with interest the article entitled “Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges” by Kewalramani et al. [1]. ∼10% of lung cancer patients are complicated with interstitial pneumonia and have a poor prognosis. Although there is a lack of evidence in this area, the article clearly summarises the current status from epidemiology to treatment, and is very informative for clinicians. However, there were three points that could be misleading to the reader, especially in the description of pharmacotherapy.This article is a correspondence to the review article on lung cancer with comorbid interstitial pneumonia, particularly with regard to pharmacotherapy. Limited evidence needs to be accurately evaluated and utilised for these patients with poor prognosis. https://bit.ly/3BGRCz4We would like to express our sincere gratitude to Yukiko Ogasawara, Yuka Onoda, Noriko Kanda and Kiriko Sato (Clinical Research Center, Kanagawa Cardiovascular and Respiratory Center, Japan) for their efforts in data collection. ER -